title: Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
abstract: In this interview with the patient representatives on the Expert Review Committee (perc) of the Pan-Canadian Oncology Drug Review (pcodr), those representatives offer their views about how to be a valuable contributing member of Canada's national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pcodr from the perspective of the patient representatives.
authors.affiliation: Pharmacoeconomics Research Unit, Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; Institute for Health Policy, Management and Evaluation, University of Toronto; and Centre for Excellence in Economic Analysis Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON.
authors.forename: J S
authors.initials: JS
authors.lastname: Hoch
authors.affiliation: Department of Philosophy, University of Leth-bridge, Lethbridge, AB.
authors.forename: M B
authors.initials: MB
authors.lastname: Brown
authors.affiliation: Expert Review Committee, Pan-Canadian Oncology Drug Review, Toronto, ON.
authors.forename: C
authors.initials: C
authors.lastname: McMahon
authors.affiliation: Expert Review Committee, Pan-Canadian Oncology Drug Review, Toronto, ON. ; Department of Psychology, University of Saskatchewan, Saskatoon, SK.
authors.forename: J
authors.initials: J
authors.lastname: Nanson
authors.affiliation: Pharmacoeconomics Research Unit, Cancer Care Ontario, and Qualitative Research, Toronto, ON.
authors.forename: L
authors.initials: L
authors.lastname: Rozmovits
keywords: Oncology drug funding; health economics; pcodr